{"disease":{"id":"transthyretin-amyloidosis-cardiomyopathy-attr-cm","name":"transthyretin amyloidosis cardiomyopathy attr cm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03842163","title":"Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology","phase":"","overall_status":"COMPLETED","enrollment_count":812,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06393465","title":"Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Pfizer","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}